相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
Michele Guida et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
Seungyeon Jung et al.
ONCOLOGIST (2022)
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
Li Zhou et al.
BMC CANCER (2022)
Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab
Kosuke Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)
Neutrophils in cancer carcinogenesis and metastasis
Shumin Xiong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab
Michael A. Postow et al.
MELANOMA RESEARCH (2020)
High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K. Bartlett et al.
CANCER (2020)
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang et al.
CLINICAL CANCER RESEARCH (2020)
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
Yalong Qi et al.
FRONTIERS IN ONCOLOGY (2020)
The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study
T. Karantanos et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si et al.
TRANSLATIONAL ONCOLOGY (2019)
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
Jiyun Lee et al.
BMC CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Bixia Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S. Carlino et al.
EUROPEAN JOURNAL OF CANCER (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
Jean Albrengues et al.
SCIENCE (2018)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung et al.
CANCER RESEARCH AND TREATMENT (2017)
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Michael R. Cassidy et al.
EBIOMEDICINE (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin Lymphoma
Alessandra Romano et al.
ONCOTARGET (2016)
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo et al.
CHINESE CLINICAL ONCOLOGY (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer
Nicole Antonio et al.
EMBO JOURNAL (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue
Gustaf Christoffersson et al.
BLOOD (2012)
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
Zhihong Chi et al.
BMC CANCER (2011)
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth
A. McGarry Houghton et al.
NATURE MEDICINE (2010)
分享论文
